Wall Street closes at a record for the first time since end of January
STATEN ISLAND - Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP), a small-cap biotech company currently trading at $6.60 with a market capitalization of $10.07 million, presented new data showing that its Phase 3-ready antibiotic ibezapolstat demonstrates selective antibacterial activity in the gut that preserves beneficial bacteria, according to a company press release. According to InvestingPro analysis, the stock has shown strong returns over the past month, despite broader market volatility.
The data, presented at the Infectious Diseases Society of America IDWeek 2025 conference in Atlanta, suggests that ibezapolstat’s favorable gut bile acid profile may contribute to preventing recurrence in patients with Clostridioides difficile infection (CDI). The company maintains a healthy financial position, with InvestingPro data showing more cash than debt on its balance sheet and a solid current ratio of 2.38, indicating strong ability to meet short-term obligations.
Researchers also presented initial evidence that this microbiome selectivity may be a class effect of Acurx’s DNA polymerase IIIC inhibitors, differentiating them from existing antibiotics like linezolid.
"Initial work on novel, lead DNA pol IIIC inhibitor compounds indicate that the positive microbiome-sparing results from our ibezapolstat studies may be a class effect," said Kevin Garey, Professor and Chair at University of Houston College of Pharmacy and Principal Investigator for microbiology aspects of the clinical trials.
Ibezapolstat has previously received FDA Qualified Infectious Disease Product and Fast-Track designations. The drug is preparing to enter Phase 3 clinical trials for CDI treatment.
In Phase 2 trials, ibezapolstat demonstrated a 96% clinical cure rate, with 100% of successfully treated patients remaining free of recurrence through one month after treatment. By comparison, the vancomycin control group had an 86% sustained cure rate.
The company reports that ibezapolstat completely eradicated colonic C. difficile by the third day of treatment while allowing beneficial gut bacteria to flourish. The drug also increased secondary bile acids, which correlates with resistance against C. difficile recurrence.
Acurx is developing ibezapolstat as part of a new class of antibiotics called Gram-Positive Selective Spectrum antibacterials that target the bacterial enzyme DNA polymerase IIIC. With the next earnings report scheduled for November 18, 2025, investors can access comprehensive analysis and additional insights through InvestingPro’s detailed research reports, which cover over 1,400 US stocks including ACXP. The stock’s negative beta of -1.29 suggests it could provide portfolio diversification benefits, as it tends to move in the opposite direction of the broader market.
In other recent news, Acurx Pharmaceuticals has received a positive opinion from the European Medicines Agency’s Pediatric Committee on its Pediatric Investigation Plan for ibezapolstat, a treatment for Clostridioides difficile infection in children. This regulatory milestone allows the company to move forward with Phase 3 clinical trials in the European Union. In addition, Acurx Pharmaceuticals has been granted a patent by the Australian Patent Office for its DNA Polymerase IIIC Inhibitors, enhancing its intellectual property portfolio. The company also announced an increase in its authorized common shares from 200 million to 250 million, following shareholder approval. This change was formalized with the Secretary of State of Delaware and took immediate effect. Shareholders further approved warrant exercises and additional proposals at a special meeting, with 63.44% of the company’s outstanding common stock represented. Moreover, H.C. Wainwright reiterated its Buy rating for Acurx Pharmaceuticals, maintaining a $31.00 price target, following these positive regulatory developments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.